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Abstract
Bee venom is a rich source of pharmacologically active substances. In this study, we identified a bumblebee (Bombus ignitus)
venom Kunitz-type serine protease inhibitor (Bi-KTI) that acts as a plasmin inhibitor. Bi-KTI showed no detectable inhibitory
effect on factor Xa, thrombin, or tissue plasminogen activator. In contrast, Bi-KTI strongly inhibited plasmin, indicating that it
acts as an antifibrinolytic agent; however, this inhibitory ability was two-fold weaker than that of aprotinin. The
fibrin(ogen)olytic activities of B. ignitus venom serine protease (Bi-VSP) and plasmin in the presence of Bi-KTI indicate that Bi-
KTI targets plasmin more specifically than Bi-VSP. These findings demonstrate a novel mechanism by which bumblebee
venom affects the hemostatic system through the antifibrinolytic activity of Bi-KTI and through Bi-VSP-mediated
fibrin(ogen)olytic activities, raising interest in Bi-KTI and Bi-VSP as potential clinical agents.
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Introduction
Serine proteases and serine protease inhibitors, which are found
in diverse organisms, are of broad interest because they have
diverse physiological functions and affect processes, such as the
immune response, hemostasis, fibrinolysis, and the elimination of
inflammation [1–3]. Serine proteases and serine protease inhib-
itors have been found in snake venom in which many serine
proteases exhibit fibrin(ogen)olytic activity [4–6] and serine
protease inhibitors demonstrate antifibrinolytic activity [7–10].
Bumblebee (Bombus spp.) venom contains three major compo-
nents: bombolitin, phospholipase A2, and serine proteases [11–14].
Our previous studies provided the first evidence of the fibrin
(ogen)olytic activity of bumblebee venom serine proteases, which
act as prothrombin activators, thrombin-like proteases, and
plasmin-like proteases [13,14]. Although several Kunitz-type
serine protease inhibitors have been reported to be present in
snake venom [7,15–17], the role of serine protease inhibitors in
bee venom remains unknown.
Although bee venom has attracted considerable interest as a
rich source of pharmacological substances [18] and has been used
traditionally for the treatment of various diseases [19], the
mechanism by which bee venom affects the hemostatic system
remains poorly understood. In this study, we showed that the
bumblebee (Bombus ignitus) venom Kunitz-type serine protease
inhibitor (Bi-KTI) is a plasmin inhibitor that exhibits antifibrino-
lytic activity. We also determined how Bi-KTI and B. ignitus
venom serine protease (Bi-VSP) are involved in fibrinolysis. The
present study demonstrates that Bi-KTI acts as an antifibrinolytic
agent, providing support for the use of Bi-KTI as a potential
clinical agent.
Results and Discussion
Bi-KTI is a bee venom Kunitz-type serine protease
inhibitor
To explore the role of serine protease inhibitors in bee venom,
we identified an expressed sequence tag (EST) for a gene encoding
a venom serine protease inhibitor (Bi-KTI) in a B. ignitus cDNA
library. Bt-KTI consists of 82 amino acids (aa), including a
predicted 24-aa signal peptide and a 58-aa mature peptide
(GenBank accession number JN381496). Database searches
showed that the mature Bt-KTI peptide contains features
consistent with snake venom Kunitz-type inhibitors [7,15–17],
including six conserved cysteine residues and a P1 site (Figure 1A).
Recombinant Bi-KTI was expressed as a 6.5-kDa peptide in
baculovirus-infected insect cells (Figure 1B). Using recombinant
Bi-KTI, we investigated the inhibitory effects of the enzyme and
found that Bi-KTI is a Kunitz-type trypsin-like inhibitor
(Figure 1C). Collectively, these data indicate that Bi-KTI is a
member of the Kunitz-type inhibitor family [7,15–17].
Bi-KTI acts as a plasmin inhibitor
Given that Bi-KTI is a Kunitz-type inhibitor [7–9], we first
assessed whether Bi-KTI inhibits plasmin by determining the time
course of human fibrin degradation. We found that Bi-KTI
significantly inhibited the degradation of fibrin into fibrin
degradation products (FDPs) (Figure 2A). To obtain direct
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activity of this inhibitor on a fibrin plate. Our results showed that
the addition of Bi-KTI led to the inhibition of the formation of a
clear area (Figure 2B), indicating that Bi-KTI inhibits plasmin by
inhibiting the degradation of fibrin into FDPs, which suggests that
Bi-KTI has an antifibrinolytic function.
We next assayed the ability of Bi-KTI to inhibit important
enzymes that belong to the hemostatic system. The results indicate
that Bi-KTI has no detectable inhibitory effect on factor Xa,
thrombin, or tPA (Figure 3A); however, Bi-KTI strongly inhibited
plasmin (Figure 3B), indicating that Bi-KTI has a role as a plasmin
inhibitor. We also compared the inhibitory ability of Bi-KTI with
that of aprotinin, which is widely used as a plasmin inhibitor
[20,21]. In this experiment, the inhibitory activity of Bi-KTI (IC50:
43.53 nM) against plasmin was approximately two-fold weaker
than that of aprotinin (IC50: 21.66 nM) (Table 1). Similarly, the
Figure 1. Bi-KTI is a Kunitz-type serine protease inhibitor. (A) The alignment of the amino acid sequences for Bi-KTI and known Kunitz-type
serine protease inhibitors. Identical residues are shown in solid boxes. The characteristic cysteine residues are indicated by solid circles. The P1
position is marked with an asterisk. The sources for the aligned sequences were B. ignitus (this study, GenBank accession no. JN381496),
Rhinoplocephalus nigrescens (GenBank accession no. B5KL37), P. textilis textilinin-4 (GenBank accession no. Q90W98), P. textilis textilinin-1 (GenBank
accession no. AF402324), Hoplocephalus stephensii (GenBank accession no. B5L5R7), and Bos taurus aprotinin (GenBank accession no. P00974). The Bi-
KTI sequence was used as a reference for the identity/similarity (Id/Si) values. (B) SDS-PAGE (left) and western blot analysis (right) of purified
recombinant Bi-KTI expressed in baculovirus-infected Sf9 insect cells. Recombinant Bi-KTI was identified using an anti-Bi-KTI antibody. (C) Enzyme
inhibition by Bi-KTI. Trypsin or chymotrypsin was incubated with increasing amounts of Bi-KTI, and the residual enzyme activity was then determined
(n=3).
doi:10.1371/journal.pone.0032269.g001
Figure 2. Bi-KTI inhibits plasmin. (A) Bi-KTI-mediated plasmin inhibition assay. The number indicates the time (in min) that fibrin was incubated
with plasmin or both plasmin and Bi-KTI. The FDPs are shown. (B) The antifibrinolytic activity of Bi-KTI. Plasmin was dropped onto fibrin plates along
with different amounts of Bi-KTI, and the plates were then incubated at 37uC for various periods of time.
doi:10.1371/journal.pone.0032269.g002
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were 3.6 nM and 1.6 nM, respectively (Table 1). To study the
mechanism of plasmin inhibition by Bi-KTI, we assessed the
formation of plasmin-Bi-KTI complexes via native gel electro-
phoresis followed by western blotting (Figure 3C). The electro-
phoretic mobility shift assay showed that Bi-KTI binds to plasmin,
indicating the formation of a plasmin-Bi-KTI complex.
The antifibrinolytic activity of Bi-KTI due to its ability to inhibit
plasmin could help alleviate the bleeding caused by plasmin-
mediated fibrin clot digestion [7–10,22]. Consequently, the ability
of Bi-KTI to inhibit plasmin suggests that Bi-KTI is an
antifibrinolytic agent.
Antifibrinolytic role of Bi-KTI
Bee venom also contains a Bi-VSP that acts as a fibrin(ogen)-
olytic serine protease [13]. Thus, we investigated whether Bi-KTI
affects Bi-VSP, plasmin, or both during fibrin(ogen)olysis by
determining the activity of Bi-VSP and plasmin in the presence of
Bi-KTI. When Bi-VSP and plasmin were not treated with Bi-KTI,
the fibrinogen was converted into fibrin by Bi-VSP and the fibrin
was degraded into FDPs by both Bi-VSP and plasmin (Figure 4).
However, the activities of Bi-VSP and plasmin in the presence of
Figure 3. Antifibrinolytic activity of Bi-KTI. (A) Inhibitory activity of Bi-KTI. Factor Xa, thrombin, or tPA was incubated with increasing amounts of
Bi-KTI, and the residual enzyme activity was determined (n=3). (B) Comparison of the inhibitory ability of Bi-KTI with that of aprotinin. Plasmin was
incubated with increasing amounts of Bi-KTI or aprotinin, and the residual enzyme activity was determined (n=3). (C) Western blot analysis of
plasmin-Bi-KTI complex formation via native gel electrophoresis. Three micrograms of plasmin were incubated with 1 mg of Bi-KTI, and the samples
(plasmin, Bi-KTI, or plasmin-Bi-KTI mixture) were resolved on a 10% polyacrylamide gel. After electrophoresis, the protein samples were incubated
with antiserum against plasmin (left) or His-tag (right). The plasmin, Bi-KTI, or plasmin-Bi-KTI complexes are shown.
doi:10.1371/journal.pone.0032269.g003
Table 1. The inhibitory activities of Bi-KTI and aprotinin
against plasmin.
IC50 (nM) Ki (nM)
Aprotinin 21.66 1.6
Bi-KTI 43.53 3.6
doi:10.1371/journal.pone.0032269.t001
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Whereas both Bi-VSP and plasmin were inhibited by Bi-KTI, the
activity of Bi-VSP in the presence of plasmin was not significantly
affected by Bi-KTI. These results show that Bi-KTI strongly
inhibited plasmin during fibrinolysis, indicating that Bi-KTI
specifically targets plasmin, as has been demonstrated for
textilinin-1, a Kunitz-type inhibitor from Pseudonaja textilis venom
[7–10]. This result further defines a specific role for Bi-KTI as a
plasmin inhibitor.
Given that each bee venom component must be in balance with
its own function, Bi-VSP and Bi-KTI appear to play important
roles in an efficient process because Bi-VSP acts as a fibrin(ogen)-
olytic agent and Bi-KTI acts as an antifibrinolytic agent. The
findings that Bi-VSP activates prothrombin and that Bi-VSP also
acts as a fibrin(ogen)olytic protease [13] suggest that Bi-VSP is
used to facilitate the spread of bee venom throughout the
bloodstream, as has been demonstrated for snake venom
fibrin(ogen)olytic enzymes, which remove fibrinogen effectively
and, thereby, reduce blood viscosity [23,24]. Given the similarity
in plasmin targeting with textilinin-1, an anti-bleeding agent [7–9],
Bi-KTI is likely to be an antifibrinolytic agent that reduces
bleeding at the sting site of victims. Taken together, our results
suggest that prothrombin activation by and the fibrin(ogen)olytic
activity of Bi-VSP and the inhibition of plasmin by Bi-KTI may
act in a cooperative manner to promote the spread of bee venom
under anti-bleeding conditions.
Conclusion
Our results reveal that bumblebee venom affects the hemostatic
system through plasmin inhibition by Bi-KTI and through
prothrombin activation and Bi-VSP-mediated thrombin- and
plasmin-like protease activities (Figure 5). These findings may
have therapeutic significance. Although the antifibrinolytic activity
of Bi-KTI must be investigated in animal models and human
studies, we propose that this protein can function as a clotting
factor and may represent a potential clinical agent.
Materials and Methods
Gene cloning and sequence analysis
A clone encoding Bi-KTI was selected from the ESTs generated
from a cDNA library produced using the venom glands of B. ignitus
worker bees [13]. Plasmid DNA was extracted using the Wizard
Mini-Prep Kit (Promega, Madison, WI) and sequenced using an
ABI 310 automated DNA sequencer (Perkin-Elmer Applied
Biosystems, Foster City, CA). The sequences were compared
using DNASIS and BLAST (http://www.ncbi.nlm.nih.gov/
BLAST).
Protein expression and purification
A baculovirus/Sf9 insect cell expression system [13] was used
for the production of recombinant Bi-KTI. A Bi-KTI cDNA
fragment containing the full-length open reading frame was
inserted into the pBAC1 vector (Clontech, Palo Alto, CA) to
generate an expression vector that drives the expression of the
recombinant protein under the control of the Autographa californica
nucleopolyhedrovirus (AcNPV) polyhedrin promoter. Recombi-
nant baculoviruses were propagated in Sf9 cells cultured in TC100
medium (Gibco BRL, Gaithersburg, MD) at 27uC. The
recombinant proteins were purified using the MagneHis
TM
Protein Purification System (Promega, Madison, WI). The protein
concentrations were determined using a Bio-Rad Protein Assay
Kit. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
western blot analysis were performed as described previously [13]
using an Enhanced Chemiluminescence Western Blotting Analysis
System (Amersham Biosciences, Piscataway, NJ).
Measurement of protease and inhibitor activity
Trypsin (400 ng, Sigma) or a-chymotrypsin (400 ng, Sigma) was
incubated in 100 mM Tris-HCl (pH 8.0) containing 20 mM
CaCl2 and 0.05% Triton X-100 with increasing amounts of Bi-
KTI at 37uC for 30 min. The residual enzyme activity was
determined at 405 nm or 410 nm using the following substrates:
Figure 4. Fibrin(ogen)olytic and antifibrinolytic activities of Bi-VSP and Bi-KTI. The fibrin(ogen)olytic activities of Bi-VSP and plasmin in the
presence of Bi-KTI were assayed. Human fibrinogen was incubated with the following: plasmin; plasmin and Bi-KTI; Bi-VSP; Bi-VSP and plasmin; or Bi-
VSP, plasmin, and Bi-KTI. The fibrin(ogen)olytic activity was then determined after various periods of time.
doi:10.1371/journal.pone.0032269.g004
Figure 5. The proposed mechanism for Bi-VSP- and Bi-KTI-
mediated fibrin(ogen)olytic and antifibrinolytic activities. Bi-
VSP activates prothrombin and degrades fibrinogen into FDPs [13]. Bi-
KTI inhibits plasmin, which degrades fibrin into FDPs.
doi:10.1371/journal.pone.0032269.g005
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(Sigma) for a-chymotrypsin. Additionally, 400 ng of human
plasmin (Sigma), thrombin (Sigma), tissue plasminogen activator
(tPA; Sigma), or factor Xa (Novagen) was incubated with
increasing amounts of Bi-KTI or aprotinin (Sigma) at 37uC for
30 min in 50 mM Tris-HCl buffer (pH 7.4), and the residual
enzyme activity was determined at 405 nm using 0.5 mM of
chromogenic substrate (Chromogenix, Mo ¨lndal, Sweden): S-2251
for plasmin, S-2238 for thrombin, S-2288 for tPA, and S-2222 for
factor Xa.
Fibrinolytic cleavage assay
Human fibrinogen (200 mg, Sigma) that had been clotted with 1
unit of thrombin in 50 mM Tris-HCl buffer (pH 7.4) containing
5 mM CaCl2 was incubated with plasmin (500 ng) or both
plasmin and Bi-KTI (16.6 ng) at 37uC. The fibrinolytic cleavage
was analyzed using 12% SDS-PAGE (10 mg/lane).
Fibrin plate assay
The fibrin plate assay was performed with 5 ml of human
fibrinogen (0.5%) clotted with three units of thrombin. Plasmin or
a mixture of plasmin and Bi-KTI was dropped onto the fibrin
plates, and the plates were incubated at 37uC for various periods of
time. The fibrinolytic activity was determined by examining the
formation of a clear area [13].
Plasmin inhibitory assay
Human plasmin (25 nM, Sigma) was incubated with increasing
amounts of Bi-KTI or aprotinin (Sigma) at 37uC for 30 min in
50 mM Tris-HCl buffer (pH 7.4), and the residual enzyme activity
was determined at 405 nm using 100 mM S-2251. The initial
reaction rate was determined by calculating the slope of the linear
portion of the kinetic curve. The inhibitory effect was expressed as
the percent reduction in the initial hydrolysis rate; the reaction rate
in the absence of inhibitor was taken as 100%. The inhibitor
concentration that decreased the rate of hydrolysis by 50% (IC50)
was determined. The values of the inhibition constants (Ki) were
calculated using the equation Ki=IC 50/(1+S/Km) [25].
Electrophoretic mobility shift assay
Plasmin (three mg) in 50 mM Tris-HCl buffer (pH 7.4)
containing 5 mM CaCl2 was mixed with 1 mg of Bi-KTI and
incubated at 37uC for 1 h. Samples were resolved on a 10%
polyacrylamide gel at 4uC. Following electrophoresis, the proteins
were blotted onto a sheet of nitrocellulose transfer membrane
(Schleicher & Schuell, Dassel, Germany), and the membrane was
blocked by incubation in a 1% bovine serum albumin (BSA)
solution and then incubated with an antiserum solution (1:1,000
v/v) against plasmin or the His-tag at room temperature for 1 h.
After washing in TBST (10 mM Tris-HCl [pH 8.0], 100 mM
NaCl, and 0.05% [w/v] Tween 20), the membrane was incubated
with horseradish peroxidase–conjugated anti-mouse IgG diluted
1:5,000 (v/v). After repeated washing, the membrane was
incubated with ECL detection reagents (Amersham Biosciences)
and exposed to X-ray film.
Fibrin(ogen)olytic assay
The fibrin(ogen)olytic assay was performed using a 96-well plate
with 200 ml of human fibrinogen (2%) per well. Each of the
following was incubated with fibrinogen in 50 mM Tris-HCl
buffer (pH 7.4) containing 5 mM CaCl2 at 37uC: plasmin; a
mixture of plasmin and Bi-KTI; Bi-VSP; a mixture of Bi-VSP and
plasmin; or a mixture of Bi-VSP, plasmin and Bi-KTI. The fibrin
clotting and FDPs were observed.
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